Settlement between XVIVO and Vivoline

XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to
three patents/patent applications owned by Vivoline Medical AB (publ) with
regard to inventions made by Stig Steen. XVIVO Perfusion and Vivoline have now
reached an agreement whereby, amongst other things, XVIVO Perfusion withdraws
its claim at Lund District Court and compensates Vivoline for trial costs in the
amount of approximately SEK 1.6 million. This sum will be charged to the first
quarter of 2015. Through this agreement, the parties' differences in regard to
the dispute have been definitively settled.

The settlement does not affect XVIVO Perfusion’s current operations and
strategy. The company's own products STEEN Solution™, which is protected by
patents granted until 2021 (in the US until 2022), and Perfadex® are not part of
the underlying dispute which the settlement applies to.

February 9, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 9, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com